Funding
Lustgarden Foundation for Pancreatic Cancer Research
The Virginia and DK Ludwig Fund for Cancer Research
The Sol Goldman Center for Pancreatic Cancer Research
Marcus Foundation (The Marcus Foundation)
John Templeton Foundation (JTF)
National Institutes of Health (NIH)
Hong Kong Research Grants Council Theme-Based Research Grant
Innovation and Technology Commission of the Hong Kong SAR Government
ARTICLE ABSTRACT
Cell-free DNA (cfDNA) concentrations from patients with cancer are often elevated compared with those of healthy controls, but the sources of this extra cfDNA have never been determined. To address this issue, we assessed cfDNA methylation patterns in 178 patients with cancers of the colon, pancreas, lung, or ovary and 64 patients without cancer. Eighty-three of these individuals had cfDNA concentrations much greater than those generally observed in healthy subjects. The major contributor of cfDNA in all samples was leukocytes, accounting for ∼76% of cfDNA, with neutrophils predominating. This was true regardless of whether the samples were derived from patients with cancer or the total plasma cfDNA concentration. High levels of cfDNA observed in patients with cancer did not come from either neoplastic cells or surrounding normal epithelial cells from the tumor's tissue of origin. These data suggest that cancers may have a systemic effect on cell turnover or DNA clearance.
The origin of excess cfDNA in patients with cancer is unknown. Using cfDNA methylation patterns, we determined that neither the tumor nor the surrounding normal tissue contributes this excess cfDNA—rather it comes from leukocytes. This finding suggests that cancers have a systemic impact on cell turnover or DNA clearance.See related commentary by Thierry and Pisareva, p. 2122.This article is featured in Selected Articles from This Issue, p. 2109
